IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 01-1693-M) (previously 13615.41USU1)

& ^(*)	(previously isoto. (reset)	至
In re Application of:	,)	3
Beck et al.)	CENTER
Serial No.: 09/895,843) Before the Examiner:) Sudhaker B. Patel	15 150 150
Filed: June 29, 2001) Art Unit: 1624	1600/2900
For: Compounds to Treat Alzheimer's Dis	sease) Confirmation No.: 5924	0
Commissioner for Patents Washington, D.C. 20231	,	

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - a. Petition for Three Month Extension of Time;
 - b. Response to the Restriction Requirement Mailed October 1, 2002; and
 - c. Postcard.
- 2. With respect to additional fees:
 - X A. Attached is a check in the amount of \$930.00.
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231-on this 31ST day of January 2003.

Date: January 31, 2003

By:

Steven J. Sarussi Reg. No. 32,784



Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for

RADEMAR Patents, Washington, D.C. 20231, (Date of Deposit).

Name Date

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 1 0 2003

(Attorney Docket No.: 01-1693-M)

In re Application of: Beck et al. Before the Examiner: Sudhaker B. Patel Serial No.: 09/895,843 Filed: June 29, 2001 Art Unit: 1624

For: Compounds to Treat Alzheimer's Disease

RESPONSE TO THE RESTRICTION REQUIREMENT MAILED OCTOBER 1, 2002

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Responsive to the Responsive to the Restriction Requirement mailed October 1, 2002, the Applicants elect the claims of Group IX, i.e., Claims 15-35, 64-98 (in part), 104-109 (in part), 116-121, 125-127, 130-131, 139-145, 147, 151-153, 156-157, 167, 173, and 175 for prosecution. Further, Applicant elect the species of Preparation 23, page 131, lines 10-11. That compound is

named $N^{1}-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-5-methyl-<math>N^{3}$, N^{3} -dipropylisophthalamide.

Claims 15, 16-21, 29-35, 64-98, 104-109, 116-121, 125-127, 130-131, 139-145, 147, 151-153, 156-157, 167, 173, and 175 encompass the elected species.

REMARKS

Allowance of the claims and passage of the case to issue are respectfully solicited. The Applicants urge the Examiner to contact the Applicants' undersigned representative as (312) 913-0001 should he believe that this would expedite prosecution of this application.

Respectfully submitted,

Dated: January 31, 2003

By:

Steven J. Savussi Reg. No. 3,784

McDonnell Boehnen
Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001